Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sophie E. Aapkes"'
Publikováno v:
Medicine (Baltimore), 100
Medicine (Baltimore), 100, 32
Medicine, 100(32):e26797. LIPPINCOTT WILLIAMS & WILKINS
Medicine (Baltimore), 100, 32
Medicine, 100(32):e26797. LIPPINCOTT WILLIAMS & WILKINS
RATIONALE: Polycystic liver disease is a rare disease characterized by the growth of numerous cysts in the liver. The liver function remains well preserved, but liver volumes can grow very large, and some patients ultimately need a liver transplantat
Autor:
Ron T. Gansevoort, Marjan van den Berg, Lucas H P Bernts, Joost P.H. Drenth, Sophie E. Aapkes, Thijs R. M. Barten
Publikováno v:
Liver International, 41, 9, pp. 2009-2019
Liver International, 41, 2009-2019
Liver International
Liver International, 41, 2009-2019
Liver International
Contains fulltext : 238413.pdf (Publisher’s version ) (Open Access) BACKGROUND AND AIMS: Patients suffering from polycystic liver disease (PLD) can develop large liver volumes, leading to physical and psychological complaints, reducing quality of l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::749523ff3d528f4d7205a93e7484b558
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/238413
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/238413
Autor:
Abigail Veldman, Lucas H P Bernts, Robbert J. de Haas, Joost P.H. Drenth, Sophie E. Aapkes, Esther Meijer, Ron T. Gansevoort
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims Recently, we performed a large randomized-controlled trial to assess the effects of the somatostatin analogue lanreotide on kidney function and kidney and liver volume in autosomal dominant polycystic kidney disease (ADPKD), the D
Autor:
Claire C J Dekkers, Iris W Koorevaar, Sophie E. Aapkes, Hiddo J.L. Heerspink, Ron T. Gansevoort, Bart J Kramers, Esther Meijer
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims The vasopressin V2 receptor antagonist tolvaptan is the first drug that was proven to ameliorate kidney function decline in ADPKD. Blockade of the vasopressin V2 receptor, however, also results in nephrogenic diabetes insipidus (N